Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: In this review, firstly we will summarize the molecular function of ApoCIII in lipoprotein metabolism. Then, we will examine the lipid-lowering potential of the pharmacological inhibition of ApoCIII based on the results of clinical trial employing Volansesorsen, the first approved antisense therapeutic oligonucleotide against ApoCIII mRNA. The future perspectives for ApoCIII inhibition will be also revised.
|
Authors | Daniele Tramontano, Simone Bini, Laura D'Erasmo, Marcello Arca |
Journal | Current opinion in lipidology
(Curr Opin Lipidol)
Vol. 33
Issue 6
Pg. 309-318
(12 01 2022)
ISSN: 1473-6535 [Electronic] England |
PMID | 36206093
(Publication Type: Review, Journal Article)
|
Copyright | Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Apolipoprotein C-III
- Triglycerides
- Lipoproteins, VLDL
- Oligonucleotides, Antisense
|
Topics |
- Humans
- Apolipoprotein C-III
(metabolism)
- Triglycerides
- Hypertriglyceridemia
(metabolism)
- Atherosclerosis
(metabolism)
- Lipoproteins, VLDL
- Oligonucleotides, Antisense
(genetics, therapeutic use)
|